

1 **PKHD1L1, A Gene Involved in the Stereociliary Coat, Causes Autosomal** 2 **Recessive Nonsyndromic Hearing Loss**

3
4 Shelby E. Redfield^{1,+}, Pedro De-la-Torre^{2,3,+}, Mina Zamani^{4,5}, Hina Khan⁶, Tyler Morris²,
5 Gholamreza Shariati^{5,7}, Majid Karimi⁸, Margaret A. Kenna^{1,2}, Go Hun Seo⁹, Sadaf Naz⁶, Hamid
6 Galehdari⁴, Artur A. Indzhukulian^{2,3,*} ^, A. Eliot Shearer^{1,3,*} ^, Barbara Vona^{10,11,*} ^

7 1. Department of Otolaryngology and Communication Enhancement, Boston Children's
8 Hospital, 300 Longwood Avenue, BCH-3129, Boston, MA 02115, USA

9 2. Mass Eye and Ear, Eaton Peabody Laboratories, Boston, Massachusetts, USA

10 3. Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, 25 Shattuck
11 Street, Boston, MA 02115, USA

12 4. Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

13 5. Narges Medical Genetics and Prenatal Diagnosis Laboratory, Kianpars, Ahvaz, Iran

14 6. School of Biological Sciences, University of the Punjab, Quaid-e-Azam Campus, Lahore
15 54590, Pakistan

16 7. Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of
17 Medical Sciences, Ahvaz, Iran

18 8. Khuzestan Cochlear Implantation Center (Tabassom), Ahvaz, Iran

19 9. 3billion, Inc., Seoul, South Korea

20 10. Institute of Human Genetics, University Medical Center Göttingen, 37073 Göttingen,
21 Germany

22 11. Institute for Auditory Neuroscience and InnerEarLab, University Medical Center Göttingen,
23 37075 Göttingen, Germany

24 * *Corresponding authors:* Artur.Indzhukulian@hms.harvard.edu,
25 Eliot.Shearer@childrens.harvard.edu, barbara.vona@med.uni-goettingen.de

26 + *Contributed equally to this work*

27 ^ *Contributed equally to this work*

1 **ORCID**

2 Shelby Redfield 0000-0002-3485-6654

3 Pedro De-la-Torre 0000-0002-2434-3345

4 Mina Zamani 0000-0002-7005-3787

5 Sadaf Naz 0000-0002-1912-0235

6 Artur A. Indzhukulian 0000-0002-2076-6818

7 A. Eliot Shearer 0000-0002-5324-4805

8 Barbara Vona 0000-0002-6719-3447

1 **Abstract**

2 Identification of genes associated with nonsyndromic hearing loss is a crucial endeavor, given
3 the substantial number of individuals who remain without a diagnosis after even the most
4 advanced genetic testing. *PKHD1L1* was established as necessary for the formation of the
5 cochlear hair-cell stereociliary coat and causes hearing loss in mice and zebrafish when
6 mutated. We sought to determine if biallelic variants in *PKHD1L1* also cause hearing loss in
7 humans.

8 Exome sequencing was performed on DNA of three families segregating autosomal recessive
9 moderate to severe nonsyndromic sensorineural hearing loss. Compound heterozygous
10 missense p.[(Gly129Ser)];p.[(Gly1314Val)], homozygous missense p.(His2479Gln) and
11 nonsense p.(Arg3381Ter) variants were identified in *PKHD1L1* that were predicted to be
12 damaging using *in silico* pathogenicity prediction methods. *In vitro* functional analysis of two
13 missense variants was performed using purified recombinant PKHD1L1 protein fragments. We
14 then evaluated protein thermodynamic stability with and without the missense variants found in
15 one of the families. *In vitro* functional assessment indicated that both engineered PKHD1L1
16 mutant p.(Gly129Ser) and p.(Gly1314Val) constructs significantly reduced the folding and
17 structural stabilities of the expressed protein fragments, providing further evidence to support
18 pathogenicity of these variants. *In silico* molecular modelling using AlphaFold2 and protein
19 sequence alignment analysis were carried out to further explore potential variant effects on
20 protein folding and stability and exposed key structural features that might suggest PKHD1L1
21 protein destabilization.

22 Multiple lines of evidence collectively associate *PKHD1L1* with nonsyndromic mild-moderate to
23 severe sensorineural hearing loss. *PKHD1L1* testing in individuals with mild-moderate hearing
24 loss may identify further affected families.

25

26 **Keywords:** Polycystic Kidney and Hepatic Disease 1-Like 1 (*PKHD1L1*), stereocilia, deafness

27 Introduction

28 Hearing loss-associated genes are implicated in the function of all parts of the delicate
29 molecular machinery that permits human hearing. The inner hair cells (IHCs) and outer hair
30 cells (OHCs) of the organ of Corti contain an apical bundle of ~100 actin-filled protrusions called
31 stereocilia. Upon sound stimulation, stereocilia bundles are deflected by pressure-induced
32 waves within the fluid-filled organ of Corti. Housing the mechanotransduction apparatus at the
33 tips of stereocilia, these bundles mediate the transformation of the mechanical stimulus into an
34 electrical signal the brain interprets as sound. While IHCs convert sound waves into nerve
35 signals, OHCs allow for non-linear amplification of the sound stimuli by changing their length in
36 response to bundle deflection, a process known as electromotility (Brownell 1990). Although
37 IHCs and OHCs have two separate and distinct functions, both sensory cell types require a
38 properly organized, functional stereocilia bundle. Stereocilia have a transiently expressed
39 surface coat, but little is understood about the function or molecular architecture of this surface
40 specialization. To date, there are over 30 genes reported to be critical for stereocilia bundle
41 morphology that are associated with sensorineural hearing loss (SNHL) in humans (Michalski
42 and Petit 2015; Petit and Richardson 2009).

43 One such stereocilia protein, polycystic kidney and hepatic disease 1-like 1 (*Pkhd11*) is critical
44 to hearing in mice (Wu et al. 2019). The *PKHD1L1* gene in humans encodes a 4,243 amino acid
45 protein, which is predicted to be composed by a large extracellular domain, a 20 amino acid
46 transmembrane domain, and a very short cytoplasmic domain of 9 residues. In mice, PKHD1L1
47 is highly enriched in both IHCs and OHCs, particularly at the tips of OHC stereocilia bundles
48 (Wu et al. 2019). It is hypothesized that this protein makes up a major component of the
49 transient stereociliary coat. Mice lacking *Pkdh11* displayed elevated Auditory Brainstem
50 Response (ABR) and Distortion Product Otoacoustic Emissions (DPOAE) thresholds in
51 response to pure tone stimuli in a progressive fashion (Wu et al. 2019). More recent data from
52 zebrafish (*Danio rerio*) with a double knockout of *pkhd11a* and *pkhd11b* (orthologs of human
53 *PKHD1L1*) show significant deficits in auditory startle response at the larval stage, consistent
54 with an early-onset auditory phenotype in zebrafish (Makrogkikas et al. 2023). Based on these
55 findings in animal models, we sought to determine whether variants in *PKHD1L1* cause hearing
56 loss in humans.

57 In this study, we propose *PKHD1L1* as a novel cause of autosomal recessive nonsyndromic
58 hearing loss in humans. We describe three unrelated families with biallelic variants in *PKHD1L1*
59 identified via exome sequencing. All three probands present bilateral congenital SNHL which is

60 moderate to severe. In addition, *in vitro* functional evaluation of two of the missense variants in
61 protein fragments show decreased stabilities, suggesting that they may negatively impact their
62 structures and molecular assembly *in vitro*.

63 **Methods**

64 **Recruitment and Clinical Assessment**

65 This study was approved by the institutional review boards of Boston Children's Hospital (IRB P-
66 00031494), University Medical Center Göttingen (No. 3/2/16), and the School of Biological
67 Sciences, University of Punjab, Lahore, Pakistan (IRB No. 00005281). Written informed consent
68 was obtained from participating members of the three families or parents for their minor
69 children.

70 The proband in family 1 derived from non-consanguineous parents ascertained as part of a
71 large clinically diverse cohort of patients with SNHL in the United States. The proband in family
72 2 derived from consanguineous parents and was ascertained as part of a large ethnically
73 diverse Middle Eastern population rare disease study. The proband in family 3 was born to
74 consanguineous parents and identified from a special education school. The parents did not
75 participate in the study.

76 Demographic, otolaryngologic, audiological, and relevant medical data were ascertained from
77 the medical records of probands. Affected individuals underwent a complete otologic evaluation.
78 Routine pure-tone audiometry was performed according to current standards and measured
79 hearing thresholds at 0.25, 0.5, 1, 2, 4, 6 and 8 kHz. Pure tone audiometry for proband 3 was
80 performed in ambient noise conditions due to lack of soundproof testing environment. The
81 probands in families 1 and 2 underwent tympanometry and speech audiometry testing. Proband
82 2 additionally underwent otoacoustic emissions testing.

83 **Exome Sequencing**

84 Genomic DNA (gDNA) from individuals in families 1 (I:1, I:2 and II:1), 2 (III:1, III:2, IV:1 and IV:2)
85 and 3 (II:1) was isolated from either buccal mucosa or whole blood using standard procedures.

86 *Family 1:* Exome sequencing was performed in a Clinical Laboratory Improvements
87 Amendments (CLIA)-certified environment (GeneDx, Gaithersburg, MD, USA). Analysis was
88 performed using the DRAGEN pipeline (Illumina, San Diego, CA, USA). Copy number variants
89 were annotated using genome analysis toolkit (GATK) and a normalized segmented depth of
90 coverage model. Variants were prioritized according to allele frequency, *in silico* predictors,

91 variant segregation, prior observations, and gene-disease association, as previously described
92 (Rockowitz et al. 2020).

93 *Family 2*: Exome sequencing for the proband was performed using the SureSelect Target
94 Enrichment v7 (Agilent Technologies, Santa Clara, CA) kit and sequenced with a NovaSeq
95 6000 (Illumina, San Diego, CA, USA) sequencer following manufacturer's protocols.
96 Bioinformatics analysis of the proband in family 2 was performed as previously described (Vona
97 et al. 2021).

98 *Family 3*: Exome sequencing for the proband was carried out at 3billion, Inc., Seoul, South
99 Korea (<https://3billion.io/index>). Briefly, coding exon regions of human genes (~22,000) were
100 captured by xGen Exome Research Panel v2 (Integrated DNA Technologies, Coralville, IA,
101 USA). The captured regions of the genome were sequenced with NovaSeq 6000 (Illumina, San
102 Diego, CA, USA). The raw genome sequencing data analysis, including alignment to the
103 GRCh37/hg19 human reference genome, variant calling and annotation, was conducted with
104 open-source bioinformatics tools including Franklin ([https://franklin.genoox.com/clinical-](https://franklin.genoox.com/clinical-db/home)
105 [db/home](https://franklin.genoox.com/clinical-db/home)) and 3billion in-house software.

106 **Variant Assessment and Validation**

107 Variants were prioritized based on population and *in silico* pathogenicity prediction software.
108 Variant minor allele frequencies were derived from gnomAD (v2.1.1 and v3.1.2) (Chen et al.
109 2022; Karczewski et al. 2020). Various pathogenicity prediction tools were used including SIFT
110 (Ng and Henikoff 2001), PolyPhen-2 (Adzhubei et al. 2010), FATHMM (Shihab et al. 2014),
111 MutationTaster (Schwarz et al. 2014), REVEL (Ioannidis et al. 2016) and CADD (Rentzsch et al.
112 2019). Visualization of amino acid substitution tolerance was supported by the MetaDome web
113 server (Wiel et al. 2019).

114 Variants were annotated using the *PKHD1L1* NM_177531.6 accession (ENST00000378402.9).
115 The GTEx Portal (GTEx consortium 2013) was referenced for assessing the location of variants
116 across the annotated *PKHD1L1* isoform (Supplementary Fig. S1).

117 *PKHD1L1* variant segregation in families 1 and 2 was confirmed using Sanger sequencing.
118 Confirmation via Sanger sequencing was not performed for the proband of family 3.

119 **Sequence analyses and structural modeling of PKHD1L1 protein**

120 We compared the PKHD1L1 isoform sequence among 10 different species (see Supplementary
121 Table S1 for more details about the selected species). The sequences were obtained from the

122 National Center for Biotechnology Information (NCBI) protein database (Supplementary Table
123 S1). First, each individual protein sequence was used to predict their signal peptides and
124 domains using the Simple Modular Architecture Research Tool (SMART) (Letunic et al. 2021).
125 Signal peptides were further predicted using the SignalP-5.0 (Almagro Armenteros et al. 2019)
126 and the Prediction of Signal Peptides (PrediSi) online servers (Hiller et al. 2004). AlphaFold2
127 modelling was used to predict the potential signal peptide cleavage site and accurately inform
128 the start and end of each predicted domain before carrying out the protein sequence alignment
129 (Mirdita et al. 2022). Since the PKHD1L1 IPT domains do not have a clear conservation pattern
130 at their IPT protein start and end sequence and connecting linker domains, AlphaFold2
131 modeling results were then combined with protein sequence alignment to better predict the
132 signal peptide, IPT domain start and end residue positions, and the location of missense
133 mutations.

134 The ClustalW algorithm (Larkin et al. 2007) on Geneious (Kearse et al. 2012) was used for the
135 sequence identity analysis using the default parameters. Alignment files from Geneious were
136 imported and color-coded in JalView with 35% conservation threshold, as previously described
137 (Kearse et al. 2012). AlphaFold2 simulations of PKHD1L1 fragments were carried out using the
138 Colabfold v1.5.2-patch server using default parameters (Mirdita et al. 2022).

139 **Cloning, expression, and purification of engineered bacterially expressed PKHD1L1** 140 **protein fragments and mutant constructs**

141 Wild-type (WT) *Mus musculus* (*Mm*) PKHD1L1 IPT1-3 and IPT5-6 were subcloned into the *NdeI*
142 and *XhoI* sites of the pET21a+ vector. Site-directed mutagenesis was applied to engineer the
143 *Mm*_PKHD1L1 IPT1-3 p.(Gly129Ser) and PKHD1L1 IPT5-6 p.(Gly1314Val) constructs using the
144 QuickChange lightning kit (Agilent Technologies). All constructs were used for protein
145 expression in Rosetta (DE3) competent cells (Novagen) and cultured in TB as reported
146 previously (De-la-Torre et al. 2018). Expressed proteins were refolded at 4 °C using conditions
147 outlined below. WT *Mm* PKHD1L1 IPT1-3 and IPT1-3 p.(Gly129Ser) were refolded by fast or
148 drop-wise dilution as previously reported for other protein families (De-la-Torre et al. 2018):
149 20 mL of pure denatured protein (0.5-1 mg/mL) was dropped into 480 mL of refolding buffer
150 containing 20 mM TrisHCl [pH 8.0], 150 mM KCl, 50 mM NaCl, 2 mM CaCl₂, 400 mM L-arginine,
151 and 2 mM D(+) glucose. *Mm* WT PKHD1L1 IPT5-6 and IPT5-6 p.(Gly1314Val) were refolded by
152 dialysis of 40 mL of eluted denatured protein at 0.5 mg/mL into 1000 mL of refolding buffer (20
153 mM TrisHCl [pH 7.5], 150 mM KCl, 50 mM NaCl, 5 mM CaCl₂, 400 mM L-arginine, 1 mM of
154 glutathione oxidized). Proteins were concentrated using 10,000 Da Amicon Ultra-15 centrifugal

155 filters and purified using size exclusion chromatography with an Akta Purifier System with the
156 S200 16/600 pg and S200 13/300 increase GL columns (GE Healthcare) in a buffer containing
157 20 mM Tris-HCl pH 7.5, 150 mM KCl, 50 mM NaCl, and 5 mM CaCl₂ to preserve the most
158 abundant endolymphatic cations. Purity of the recombinant and mammalian proteins was
159 analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

160 **Nanoscale Differential Scanning Fluorimetry**

161 WT *Mm* PKHD1L1 IPT1-3 and IPT5-6 protein fragments and their respective missense IPT1-3
162 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) proteins were used for functional evaluation *in vitro*.
163 Thermodynamic evaluation and folding stabilities of these constructs in solution were carried out
164 using nano differential scanning fluorimetry (NanoDSF). Pure proteins were concentrated to 0.5-
165 1 mg/mL for NanoDSF using a Prometheus NT.48 (Nanotemper) and scanned between 20-95
166 °C with a pre-stabilization phase of 1 min and a temperature slope of 2 °C/min (37 min in total).
167 Data were processed using a PR.ThermControl v2.1.2 software and plotted using GraphPad
168 Prism. At least two biological replicates were used for each experiment. Each protein
169 preparation was independently expressed and refolded at least two times (two biological
170 replicates), and evaluated independently on NanoDSF. Each NanoDSF scan was run in parallel
171 using at least four separate capillary tubes for each biological replicate. Each result per
172 biological replicate represents average values of these measurements. Protein folding analysis
173 results were plotted as a relationship of the normalized F350/F330 (%) ratio intensities (T_{onset}).
174 The first derivative of F350/F330 (%) intensities were plotted to obtain the thermal unfolding
175 transition midpoints (T_m).

176 **Results**

177 **Clinical Genetics**

178 **Family 1 (Fig. 1):** The proband is a 10-15-year-old female born to healthy nonconsanguineous
179 parents. She referred bilaterally on newborn hearing screening. Pure tone audiometry has been
180 performed approximately every 6 months and consistently demonstrated a slowly progressive
181 mild to moderate SNHL bilaterally. Between the ages of 0-5 years and 10-15 years, there is a
182 decrease in pure tone average (PTA) of 5 dB for the right ear and 8 dB for the left ear. PTA was
183 41.25 and 38.75 in the right and left ears, respectively at age 0-5. Most recent audiometric
184 testing showed PTA of 45 and 48.75 in the right and left ears, respectively. Speech audiometry
185 at most recent evaluation (age 10-15 years) demonstrates a 90%-word recognition at a
186 comfortable listening level. Speech recognition threshold (SRT) is 45 dB bilaterally. There is a

187 history of monthly episodes of benign paroxysmal positional vertigo (BPPV) which resolved after
188 Epley maneuver. Imaging studies of the inner ear were not performed. An electrocardiogram
189 and ophthalmology exam were normal. Cytomegalovirus testing was negative. There were no
190 dysmorphic facial features, neurological or developmental abnormalities, or other pertinent
191 history. Exome sequencing revealed candidate variants only in *PKHD1L1*. Other variants were
192 excluded based on a combination of *in silico* predictors, allele frequency, and prior clinical
193 observation. The proband was compound heterozygous for missense variants, p.(Gly129Ser)
194 and p.(Gly1314Val) (Table 1) that segregated within the trio in a Mendelian recessive manner
195 (residue numbering corresponds to the NCBI human (*Hs*) sequence including the signal
196 peptide, Supplementary Table S1).

197 The p.(Gly129Ser) substitution resides in exon 4 of 78 in *PKHD1L1* and has a maximum allele
198 frequency (MAF) of 0.001471% in gnomAD (v3.1.2). This variant is predicted to be deleterious
199 to protein structure and function via *in silico* predictors (Table 1). This nonpolar glycine to polar
200 serine substitution occurs at the tip of the PKHD1L1 IPT1 domain (Fig. 2b-d). This locus is
201 predicted to be somewhat tolerant to missense substitution (Supplementary Fig. S2). On the
202 other hand, the p.(Gly1314Val), located in exon 32 of 78 in *PKHD1L1*, has a MAF of 0.07204%
203 (gnomAD, v3.1.2) and is also predicted to be deleterious to protein structure and function by *in*
204 *silico* predictors (Table 1). This glycine to valine substitution occurs within the PKHD1L1 IPT6
205 domain region (Fig. 2b-d). This locus is predicted to be intolerant to missense substitution
206 (Supplementary Fig. S2).

207 **Family 2 (Fig. 1):** The proband is a 6-10-year-old male born to healthy consanguineous
208 parents. Congenital SNHL was suspected and later clinically diagnosed. It has progressed to a
209 bilateral moderate to severe degree. Pure tone audiometry shows moderate to severe SNHL in
210 all frequencies. Speech audiometry understanding is 100% at a comfortable listening level, and
211 the otoacoustic emissions test is the reference on both ears. His SRT is 60 dB and his speech
212 discrimination score (SDS) is 100% at the intensity level of 80 dB. The proband currently uses
213 hearing aids bilaterally. There have been no vestibular or movement abnormalities. Exome
214 sequencing revealed that the proband was homozygous for the p.(Arg3381Ter) nonsense
215 variant that resided in a ~28 Mb run of homozygosity (Table 1). All other variants were excluded
216 on the basis of segregation (Supplementary Table S2). Sanger sequencing at this locus
217 confirmed the homozygous variant and revealed that the parents were both heterozygous
218 carriers of the *PKHD1L1* variant.

219 The p.(Arg3381Ter) variant is located in exon 62 of 78 and identified with a MAF of 0.01936% in
220 population databases (gnomAD, v3.1.2). This variant occurs in a region with parallel beta-helix
221 (Pbh1) repeats (Fig. 2b and Supplementary Fig. S3 for residue conservation), introducing a
222 premature stop codon that is predicted to result in the loss of approximately 20% of the
223 transcript (~ 882 amino acids), including those encoding the transmembrane domain, and could
224 potentially cause nonsense mediated decay. However, if expressed in a truncated form, lack of
225 the transmembrane domain is likely to impair proper localization of PKHD1L1 in the cell
226 membrane or might induce unconventional secretion of PKHD1L1 protein fragments.

227 **Family 3 (Fig. 1):** The proband was a 10-15-year-old male with congenital SNHL born to
228 healthy consanguineous parents. Audiometric testing demonstrated a bilateral severe SNHL. No
229 further follow up was possible for the affected individual. Exome data analysis revealed two
230 homozygous missense variants of interest; one in *PKHD1L1* and one in *MYO7A*
231 (NM_000260.4:c.1123C>G, p.(Leu375Val)). The homozygous variant in *MYO7A* was
232 deprioritized given uncertain and neutral *in silico* predictions with respect to impact on protein
233 structure and function (Supplementary Table S2).

234 The p.(His2479Gln) substitution is located in exon 49 of 78 and is identified at a MAF of
235 0.3107% in population databases (gnomAD, v3.1.2). This positively charged histidine to neutral
236 glutamine substitution is located in a topological region with an unpredicted domain structure
237 when using the SMART prediction tool (Fig. 2b).

238 **Investigating the conservation of the mutated residue positions throughout evolution**

239 All three variants do not appear to cluster in any particular region of the PKHD1L1 isoform that
240 was used for alignment and further analysis (Supplementary Fig. S1). In comparing the longest
241 PKHD1L1 isoform sequences among 10 different species, we uncovered an overall amino acid
242 sequence identity of 79.2 % (Supplementary Fig. S3) across all 10 species. Notably, *Mm* and
243 *Hs* PKHD1L1 share 81.8% of amino acid sequence identity (when comparing for identical sites
244 excluding the signal peptides), suggesting high protein sequence conservation between the two
245 species. Although some previous studies report protein sequence alignments and predictions of
246 PKHD1L1 IPT domains (Hogan et al. 2003), an in-depth analysis was necessary to more
247 accurately predict the signal peptide cleavage sites, as well as the starting and ending residues
248 for each IPT domain. The location of the native Gly126, Gly1314, and His2479 residues, where
249 the reported missense variants were detected, are highly conserved across a diverse set of the
250 10 different PKHD1L1 orthologues analyzed (Fig. 2d-e, Fig. 3a, and Supplementary Fig. S3 and
251 Fig. S4).

252 **AlphaFold2 modeling of PKHD1L1 substitutions**

253 PKHD1L1 has 14 predicted IPT extracellular-domain repeats of similar fold but with non-
254 identical protein sequence and labeled as IPT1 to IPT14 from its N-terminal to C-terminal end,
255 and other key domain features (Fig. 2b). The AlphaFold2 model of *Hs* WT IPT1-2 and its mutant
256 p.(Gly129Ser) shows no apparent differences between their predicted structures (Fig. 2f-g),
257 likely because the small side chain carrying this residue is located on a loop region exposed to
258 the solvent. More specifically, the p.(Gly129Ser) variant is located within the connecting loop
259 between the β -strand 6-7 of IPT1, close to a potential disulphide bond formed by p.Cys100 and
260 p.Cys86, also found in plexin-like domains (Fig. 2g). Changes of the polarity or the electrostatic
261 potential of this loop by p.(Gly129Ser) might cause structural changes or altered loop dynamics
262 in IPT1 (Krieger et al. 2005). We also generated AlphaFold2 models for *Hs* IPT5-6 consistent
263 with the expected IPT plexin-like folding for this structure (Fig. 2h-i). According to this structural
264 model, the *Hs* p.(Gly1314Val) mutation is also located at the connecting loop between the β -
265 strand 6-7 of IPT6 (Fig. 2h-j). Furthermore, the p.(Gly1314Val) variant is located within the
266 connecting area between IPT5 and IPT6, and the AlphaFold2 model suggests a structural
267 change for this specific fragment (Fig. 2i-j).

268 In a previous study, authors used protein sequence analysis of PKHD1, PKHD1L1 and TMEM2
269 reporting that PKHD1 and PKHD1L1 share two regions of significant sequence homology with
270 TMEM2 (Hogan et al. 2003). AlphaFold2 modelling of the third variant, p.(His2479Gln) and
271 surrounding PKHD1L1 region, revealed a high structural homology with a *Hs* TMEM2 protein
272 (Fig. 3). We identified that this region features a conserved (throughout 10 different PKHD1L1
273 species, and Supplementary Fig. S4) p.His2479 residue (p.His552 in *Hs* TMEM2, Fig. 3a; PDB:
274 8C6I (Niu et al. 2023)) reported to form a nickel-finger binding site, which might mediate
275 catalytic functions in TMEM2. Disruption of this site in PKHD1L1 and TMEM2 might impair
276 cation binding (Fig. 3a-f and Supplementary Fig. S3 and S4) and suggests a potential
277 deleterious effect for this variant on protein structure and function. This locus is predicted
278 neutral in terms of tolerance to missense substitution (Supplementary Fig. S2).

279 **Functional testing of the p.(Gly129Ser) and p.(Gly1314Val) substitutions**

280 Next, we cloned, expressed, and purified WT *Mm* PKHD1L1 IPT1-3 and IPT5-6 protein
281 fragments as well as the respective IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) mutant
282 constructs using size-exclusion chromatography (SEC) (Supplementary Fig. S5). These protein
283 constructs represent key regions of the complete extracellular domain of PKHD1L1 where these
284 mutations might locally affect the structural assembly of the protein. The thermodynamic and

285 folding stabilities were measured using NanoDSF to assess the protein stabilities in solution for
286 WT PKHD1L1 protein fragments and compared to fragments carrying missense mutations (Fig.
287 4 and Supplementary Fig. S5). For WT IPT1-3, the T_{onset} (melting temperature at which
288 unfolding begins) was measured at a maximum of 58 °C, while the T_{onset} for IPT1-3
289 p.(Gly129Ser) variant was 52 °C (a 6 °C decrease, Fig. 4 and Supplementary Fig. S5). In
290 addition, there was a decrease on the T_m (melting temperature or point at which 50% of the
291 protein is unfolded) of ~ 4 °C comparing different thermal transition points between WT and the
292 IPT1-3 p.(Gly129Ser) variant (Fig. 4a). These measurements strongly suggest that the
293 p.(Gly129Ser) variant affects PKHD1L1 protein stability within this region.

294 Similarly, NanoDSF measurements for WT *Mm* PKHD1L1 IPT5-6 and *Mm* IPT5-6
295 p.(Gly1314Val) showed a T_{onset} of 35.48 °C and 28.56 °C, respectively (~ 7 °C decrease, Fig. 4
296 and Supplementary Fig. S5). Additionally, WT *Mm* PKHD1L1 IPT5-6 showed a melting
297 temperature T_m of 45.10 °C, while the mutant IPT5-6 p.(Gly1314Val) displayed a decrease on
298 this T_m to 36.6 °C (decreasing the temperature ~ 8.6 °C) (Fig. 4b). These results confirm that
299 both IPT1-3 p.(Gly129Ser) and IPT5-6 p.(Gly1314Val) variants indeed significantly decrease the
300 thermal and folding stabilities of these PKHD1L1 protein constructs.

301 Discussion

302 A majority of congenital SNHL is attributable to a genetic etiology, and clinical genetic testing for
303 known SNHL genes is an established standard of care in the diagnostic evaluation of bilateral
304 SNHL in pediatric patients (Shearer and Smith 2015; Smith et al. 2005). There are over 120
305 known genetic causes of nonsyndromic hearing loss, and gene panel tests are recommended to
306 facilitate accurate and timely genetic diagnosis of SNHL (<https://hereditaryhearingloss.org>).
307 However, despite advances in genetic testing for SNHL, the diagnostic yield for SNHL ranges
308 from 22.5% to 55.7% with an average of about 40% (Downie et al. 2020; Perry et al. 2023;
309 Rouse et al. 2022; Sloan-Heggen et al. 2016). The identification of novel hearing loss genes is
310 critical to improving diagnostic rates, thus impacting care and management for individuals with
311 SNHL.

312 PKHD1L1 is predominantly expressed in the OHC stereocilia by P0 to P12 with a basal-to-
313 apical (decreasing) expression gradient and is a major component of the stereocilia surface coat
314 (Wu et al. 2019). *Pkhd1l1*-deficient mice lack the surface coat at the stereocilia tips and exhibit
315 progressive SNHL by ABR and DPOAE measurements, starting as early as 3 weeks. The two
316 functional hypotheses of PKHD1L1 expression at the stereocilia include that it may be required

317 for the correct localization of other stereocilia proteins or during the development of attachment
318 crowns at the stereocilia to secure the tectorial membrane to the bundle. This immature
319 attachment could manifest as a persisting relaxed tectorial membrane coupling (Wu et al. 2019).
320 Still, it is unknown whether PKHD1L1 is the only component of the stereocilia coat. Recently,
321 *pkhd1l1* was shown to play a critical role in regulating hearing in zebrafish (Makrogkikas et al.
322 2023). *pkhd1l1* has a ubiquitous expression pattern and is sustained for most of embryonic
323 development (Makrogkikas et al. 2023). Through depletion of the two paralogous genes
324 (*pkhd1l1a* and *pkhd1l1b*), double mutant zebrafish exhibited significant hearing loss from the
325 larval stage (6 days post fertilization) which differs compared to progressive hearing loss in the
326 mouse (Wu et al. 2019).

327 The degree of hearing impairment in the patients we present is fairly broad: The proband in
328 family 1, with p.[(Gly129Ser)];p.[(Gly1314Val)] compound heterozygous variants, was
329 diagnosed with congenital hearing impairment that remains mild to moderate at the age of 10-15
330 years; the proband in family 2, with a homozygous p.(Arg3381Ter) variant, already showed
331 moderate to severe SNHL at the age of 6-10 years; and the proband in family 3, at the age of
332 10-15 years, showed severe hearing impairment attributed to the homozygous p.(His2479Gln)
333 variant. While we have identified individuals in three families with variants in *PKHD1L1*, this
334 study highlights the necessity for an extended case series with longitudinal audiological follow
335 up and functional studies to assess variant effects of patient-specific perturbations on
336 development, maturation, and function of the auditory system, as well as explore the potential of
337 accelerated effects of age, noise, or trauma on progression, which remain as current major
338 limitations. Interestingly, the *PKHD1L1* gene has been suggested to be associated with
339 adult-onset hearing loss (Lewis et al. 2023). Since the studied variants are also located in
340 different residue positions in the PKHD1L1 protein sequence, the broad range of hearing
341 impairment from these patients might suggest that these variants differentially impact the protein
342 expression, folding, and/or the stability and function of PKHD1L1.

343 Thus, we also investigated the conservation of the mutated residue positions throughout
344 evolution. Multiple sequence alignments of the complete PKHD1L1 amino acid sequence from
345 10 different species were analysed and found to be highly conserved. This suggests that these
346 native residues might be critical to protein folding and assembly. Therefore, variants in these
347 positions might disrupt protein function and potentially cause hearing impairment *in vivo*.

348 To further predict how these PKHD1L1 mutant variants might affect the PKHD1L1 protein at the
349 structural level, we modelled the structures of the individual domains carrying reported variants

350 (Fig. 2f-i and Fig. 3b-e). The p.(Gly129Ser) substitution in IPT1 was not predicted to exert an
351 apparent structural difference. We speculate that instead changes of the polarity or the
352 electrostatic potential of the β -strand linker loop by p.(Gly129Ser) might alter loop dynamics in
353 IPT1. Interestingly, both glycine substitutions p.(Gly129Ser) and p.(Gly1314Val) are located
354 within the same connecting loop between β -strand 6-7 in IPT1 and IPT6, respectively. While the
355 AlphaFold2 model of the p.(Gly129Ser) mutant shows no apparent structural changes in the
356 predicted structure (Fig. 2f), the AlphaFold2 model of p.(Gly1314Val) shows a conformation
357 change, likely due to steric hindrance on the structure (Fig. 2i). Finally, we also mapped the
358 location of the p.(His2479Gln) using structural modeling by AlphaFold2 (Fig. 3, Supplementary
359 Fig. 4). Our results indicate that the His2479 position (from 10 different species) is 100%
360 conserved with a *Hs* TMEM2 protein (PDB: 8C6I), a regulator of the hyaluronan metabolism
361 (Fig. 3a and 3e-f) (Sato et al. 2023). Interestingly, experiments suggest that TMEM2 activity is
362 calcium-dependent (Yamamoto et al. 2017) and TMEM2 has been previously studied for its
363 structural similarities with the *CEMIP* deafness gene candidate (Yoshida et al. 2013).

364 Since the p.(Arg3381Ter) introduces a stop codon that would prevent the translation and
365 expression of the transmembrane domain of PKHD1L1 (Fig. 2b), the proper localization of
366 PKHD1L1 in the cell membrane is expected to be affected. Because the helical peptide of
367 PKHD1L1 transmembrane domain is predicted between p.Ile4211-4231Ala (850 amino acids
368 downstream from the Arg3381 site from the PKHD1L1 N-terminal towards the C-terminal end),
369 this large portion of the protein will not be expressed (Fig. 2b-c, Supplementary Fig. S3). This is
370 likely to impair the proper folding, trafficking, and insertion of PKHD1L1 in the stereocilia-plasma
371 membrane, or even result in secretion of PKHD1L1 extracellular fragments that could
372 progressively affect hearing function. Interestingly, secreted versions of extracellular PKHD1L1
373 have been found in supernatant solution from platelet cells (Maynard et al. 2007) and their
374 soluble concentrations could be modulated by protease inhibitors (Fong et al. 2011), suggesting
375 potential cleavage sites in *Hs* PKHD1L1. However, the role of these cleaved extracellular
376 PKHD1L1 protein fragments is still unknown.

377 Our NanoDSF thermal folding analysis showed that both T_{onset} and T_m values decreased in the
378 presence of the p.(Gly129Ser) and p.(Gly1314Val) variants. The T_m measurements using
379 NanoDSF showed p.(Gly129Ser), located in a loop, decreases the stability of IPT1 and further
380 showed how this variant propagates its destabilizing effects to the neighboring IPT2 and IPT3
381 (Fig. 2b, Fig. 4a, and Supplementary Fig. S5). Likely, the p.(Gly1314Val) variant also alters the
382 stability of the loop and the chemical environment in the IPT5-IPT6 connection, since the

383 measured folding stability showed an 8.6 °C decrease of unfolding temperature between WT
384 IPT5-6 fragment and the p.(Gly1314Val) variant (Fig. 4). This is the first study showing strong
385 evidence to support how missense variants locally affect the structural folding and stability of
386 PKHD1L1 fragments *in vitro*. Given the high conservation rate of 81.8% in amino acid sequence
387 identity between the *Hs* and *Mm* PKHD1L1, and the 100% conservation of the mutated sites
388 across the species analyzed, we believe our findings using *Mm* PKHD1L1 protein fragments
389 can be directly applied to *Hs* PKHD1L1. Future functional studies involving full-length protein
390 purification would allow for better understanding of various effects such variants might have on
391 the stability of the entire PKHD1L1 extracellular domain, its protein expression and proper
392 localization, which might be linked to the progression and hearing loss severity. Furthermore,
393 studies focused on uncovering the influence of mutations on the structure of the complete
394 PKHD1L1 extracellular domain will help in understanding the role of PKHD1L1 in hearing
395 function and beyond, since the PKHD1L1 has been suggested as a tumor suppressor (Yang et
396 al. 2023) and a human cancer biomarker (Kafita et al. 2023; Wang et al. 2023; Zheng et al.
397 2019).

398 Additional syndromic involvement was excluded in our three patients. However, in addition to
399 hearing impairment, disruption of PKHD1L1 has also been associated with increased
400 susceptibility to pentylentetrazol-induced seizures in mice indicating a possible role in
401 maintenance of neuronal excitability in the central nervous system (Yu et al. 2023). PKHD1L1 is
402 expressed in the hippocampus and cerebral cortex in adult WT mice. Knockdown of PHKD1L1
403 using PHKD1L1-shRNA or PHKD1L1-shRNA-AAV increased susceptibility of seizures as
404 indicated by increased epileptiform bursting activity in cultured hippocampal neurons and
405 pentylentetrazol-induced seizures of mice following knockdown, suggesting a role for
406 PKHD1L1 in the maintenance of normal excitation-inhibition balance (Yu et al. 2023). Although
407 these findings have not been validated in *Pkhd111*-knockout mice, an open question remains as
408 to whether similar pleiotropic effects paralleling, for example, the various phenotypes caused by
409 pathogenic variants in *TBC1D24* may also occur as more *PKHD1L1* patients are discovered.
410 The gene-phenotype relationship of *TBC1D24* is extensive and includes both autosomal
411 dominant (DFNA65, OMIM 616044) and recessive (DFNB86, OMIM 614617) nonsyndromic
412 deafness, as well as familial infantile myoclonic epilepsy (FIME, OMIM 605021) with or without
413 deafness, early infantile epileptic encephalopathy (EIEE16, OMIM 615338), progressive
414 myoclonic epilepsy (PME, OMIM 310370), or deafness, onychodystrophy, osteodystrophy,
415 impaired intellectual development, and seizures syndrome (DOORS, OMIM 220500) (as
416 reviewed by Mucha et al. 1993; Rehman et al. 2017). Further reporting of variants in *PKHD1L1*

417 will be critical to discovering a potential parallel between *PKHD1L1* and the complex syndromes
418 using the *TBC1D24* analogy.

419 Finally, we conclude with a cautionary note for diagnostic laboratories, as this work serves as an
420 extended invitation to include *PKHD1L1* screening in their future patient diagnostic screening.
421 Determination of pathogenicity of genes causing hearing loss relies on multiple lines of
422 supporting evidence. However, in the case of large genes with large amounts of natural
423 variation, like *PKHD1L1*, the allele frequency criteria, specifically the PM2_Supporting
424 pathogenicity criteria, becomes a point of contention for classification. The PM2_Supporting
425 criterion as proposed by the ACMG/AMP hearing loss expert panel specification have calculated
426 a ≤ 0.00007 frequency for autosomal recessive disorders to trigger application (Oza et al. 2018).
427 With MAFs of 0.0007204 in the non-European Finnish and 0.003107 in the South Asian
428 populations (gnomAD v3.1.2), the c.3941G>T, p.(Gly1314Val) and c.7437C>A, p.(His2479Gln)
429 variants exceeded the ACMG/AMP criteria with hearing loss expert panel specification ,
430 respectively, and suggests the potential for missed diagnoses if the proposed frequency is
431 applied for variant filtering (Oza et al. 2018). This merits attention because the PM2 criterion is
432 most commonly applied among the criteria for hearing loss variant classification (Kim et al.
433 2022). Given the large size of *PKHD1L1* and that more missense variants are observed than
434 expected ($Z = -0.72$, o/e = 1.04 (1.02 – 1.08)) minor allele frequency threshold usage should be
435 carefully assessed for this gene. This study is a call to clinical laboratories to include careful
436 screening of *PKHD1L1* biallelic variants in patients with a hearing loss ranging from mild-
437 moderate to severe.

438 **Conclusion**

439 Here we provide data to support *PKHD1L1* as a cause of human nonsyndromic autosomal
440 recessive congenital, mild-moderate to severe hearing loss. We demonstrated that all reported
441 missense variants are of residues highly conserved throughout evolution, suggesting that the
442 native residues are key for protein folding and function, while variants in these sites affect the
443 thermal-folding stability of *PKHD1L1* fragments in solution. Inclusion as a hearing loss gene is
444 supported by multiple families segregating plausible variants, *in vitro* functional data confirming
445 the impact of variants, as well as previously published mouse and zebrafish models
446 demonstrating hearing loss. Further research will be needed to determine the effect of age,
447 noise, or trauma on progression of hearing loss.

448 References

- 449
- 450 Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS,
451 Sunyaev SR (2010) A method and server for predicting damaging missense mutations.
452 *Nat Methods* 7: 248-9. <https://doi.org/10.1038/nmeth0410-248>
- 453 Almagro Armenteros JJ, Tsirigos KD, Sonderby CK, Petersen TN, Winther O, Brunak S, von
454 Heijne G, Nielsen H (2019) SignalP 5.0 improves signal peptide predictions using deep
455 neural networks. *Nat Biotechnol* 37: 420-423. <https://doi.org/10.1038/s41587-019-0036-z>
- 456 Brownell WE (1990) Outer hair cell electromotility and otoacoustic emissions. *Ear Hear* 11: 82-
457 92. <https://doi.org/10.1097/00003446-199004000-00003>
- 458 Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, Alföldi J, Watts NA, Vittal C,
459 Gauthier LD, Poterba T, Wilson MW, Tarasova Y, Phu W, Yohannes MT, Koenig Z,
460 Farjoun Y, Banks E, Donnelly S, Gabriel S, Gupta N, Ferriera S, Tolonen C, Novod S,
461 Bergelson L, Roazen D, Ruano-Rubio V, Covarrubias M, Llanwarne C, Petrillo N, Wade
462 G, Jeandet T, Munshi R, Tibbetts K, Consortium gP, O'Donnell-Luria A, Solomonson M,
463 Seed C, Martin AR, Talkowski ME, Rehm HL, Daly MJ, Tiao G, Neale BM, MacArthur
464 DG, Karczewski KJ (2022) A genome-wide mutational constraint map quantified from
465 variation in 76,156 human genomes. *bioRxiv*: 2022.03.20.485034.
466 <https://doi.org/10.1101/2022.03.20.485034>
- 467 Choudhary D, Narui Y, Neel BL, Wimalasena LN, Klanseck CF, De-la-Torre P, Chen C, Araya-
468 Secchi R, Tamilselvan E, Sotomayor M (2020) Structural determinants of protocadherin-
469 15 mechanics and function in hearing and balance perception. *Proc Natl Acad Sci U S A*
470 117: 24837-24848. <https://doi.org/10.1073/pnas.1920444117>
- 471 Consortium G (2013) The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 45: 580-5.
472 <https://doi.org/10.1038/ng.2653>
- 473 De-la-Torre P, Choudhary D, Araya-Secchi R, Narui Y, Sotomayor M (2018) A Mechanically
474 Weak Extracellular Membrane-Adjacent Domain Induces Dimerization of Protocadherin-
475 15. *Biophys J* 115: 2368-2385. <https://doi.org/10.1016/j.bpj.2018.11.010>
- 476 Downie L, Halliday J, Burt R, Lunke S, Lynch E, Martyn M, Poulakis Z, Gaff C, Sung V, Wake
477 M, Hunter MF, Saunders K, Rose E, Lewis S, Jarmolowicz A, Phelan D, Rehm HL,
478 Melbourne Genomics Health A, Amor DJ (2020) Exome sequencing in infants with
479 congenital hearing impairment: a population-based cohort study. *Eur J Hum Genet* 28:
480 587-596. <https://doi.org/10.1038/s41431-019-0553-8>
- 481 Fong KP, Barry C, Tran AN, Traxler EA, Wannemacher KM, Tang HY, Speicher KD, Blair IA,
482 Speicher DW, Grosser T, Brass LF (2011) Deciphering the human platelet sheddome.
483 *Blood* 117: e15-26. <https://doi.org/10.1182/blood-2010-05-283838>
- 484 Hiller K, Grote A, Scheer M, Munch R, Jahn D (2004) PrediSi: prediction of signal peptides and
485 their cleavage positions. *Nucleic Acids Res* 32: W375-9.
486 <https://doi.org/10.1093/nar/gkh378>
- 487 Hogan MC, Griffin MD, Rossetti S, Torres VE, Ward CJ, Harris PC (2003) PKHDL1, a homolog
488 of the autosomal recessive polycystic kidney disease gene, encodes a receptor with
489 inducible T lymphocyte expression. *Hum Mol Genet* 12: 685-98.
- 490 Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li Q,
491 Holzinger E, Karyadi D, Cannon-Albright LA, Teerlink CC, Stanford JL, Isaacs WB, Xu J,
492 Cooney KA, Lange EM, Schleutker J, Carpten JD, Powell IJ, Cussenot O, Cancel-Tassin
493 G, Giles GG, MacInnis RJ, Maier C, Hsieh CL, Wiklund F, Catalona WJ, Foulkes WD,
494 Mandal D, Eeles RA, Kote-Jarai Z, Bustamante CD, Schaid DJ, Hastie T, Ostrander EA,
495 Bailey-Wilson JE, Radivojac P, Thibodeau SN, Whittemore AS, Sieh W (2016) REVEL:
496 An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J*
497 *Hum Genet* 99: 877-885. <https://doi.org/10.1016/j.ajhg.2016.08.016>

- 498 Jaiganesh A, De-la-Torre P, Patel AA, Termine DJ, Velez-Cortes F, Chen C, Sotomayor M
499 (2018) Zooming in on Cadherin-23: Structural Diversity and Potential Mechanisms of
500 Inherited Deafness. *Structure* 26: 1210-1225 e4.
501 <https://doi.org/10.1016/j.str.2018.06.003>
- 502 Kafita D, Nkhoma P, Dzobo K, Sinkala M (2023) Shedding Light on the Dark Genome: Insights
503 into the Genetic, CRISPR-based, and Pharmacological Dependencies of Human
504 Cancers and Disease Aggressiveness. *bioRxiv*: 2023.08.15.552589.
505 <https://doi.org/10.1101/2023.08.15.552589>
- 506 Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL, Laricchia
507 KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes
508 D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K,
509 Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE,
510 Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M,
511 Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M,
512 Donnelly S, Ferreira S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne
513 C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M,
514 Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Genome Aggregation Database
515 C, Neale BM, Daly MJ, MacArthur DG (2020) The mutational constraint spectrum
516 quantified from variation in 141,456 humans. *Nature* 581: 434-443.
517 <https://doi.org/10.1038/s41586-020-2308-7>
- 518 Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A,
519 Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A (2012) Geneious
520 Basic: an integrated and extendable desktop software platform for the organization and
521 analysis of sequence data. *Bioinformatics* 28: 1647-9.
522 <https://doi.org/10.1093/bioinformatics/bts199>
- 523 Kim SY, Kim BJ, Oh DY, Han JH, Yi N, Kim NJ, Park MK, Keum C, Seo GH, Choi BY (2022)
524 Improving genetic diagnosis by disease-specific, ACMG/AMP variant interpretation
525 guidelines for hearing loss. *Sci Rep* 12: 12457. <https://doi.org/10.1038/s41598-022-16661-x>
- 526
- 527 Krieger F, Moglich A, Kiefhaber T (2005) Effect of proline and glycine residues on dynamics and
528 barriers of loop formation in polypeptide chains. *J Am Chem Soc* 127: 3346-52.
529 <https://doi.org/10.1021/ja042798i>
- 530 Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F,
531 Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG (2007) Clustal W
532 and Clustal X version 2.0. *Bioinformatics* 23: 2947-8.
533 <https://doi.org/10.1093/bioinformatics/btm404>
- 534 Letunic I, Khedkar S, Bork P (2021) SMART: recent updates, new developments and status in
535 2020. *Nucleic Acids Res* 49: D458-D460. <https://doi.org/10.1093/nar/gkaa937>
- 536 Lewis MA, Schulte J, Matthews L, Vaden KI, Steves CJ, Williams FMK, Schulte BA, Dubno JR,
537 Steel KP (2023) Accurate phenotypic classification and exome sequencing allow
538 identification of novel genes and variants associated with adult-onset hearing loss.
539 *medRxiv*. <https://doi.org/10.1101/2023.04.27.23289040>
- 540 Makrogkikas S, Cheng RK, Lu H, Roy S (2023) A conserved function of Pkhd111, a mammalian
541 hair cell stereociliary coat protein, in regulating hearing in zebrafish. *J Neurogenet*: 1-8.
542 <https://doi.org/10.1080/01677063.2023.2187792>
- 543 Maynard DM, Heijnen HF, Horne MK, White JG, Gahl WA (2007) Proteomic analysis of platelet
544 alpha-granules using mass spectrometry. *J Thromb Haemost* 5: 1945-55.
545 <https://doi.org/10.1111/j.1538-7836.2007.02690.x>
- 546 Michalski N, Petit C (2015) Genetics of auditory mechano-electrical transduction. *Pflugers Arch*
547 467: 49-72. <https://doi.org/10.1007/s00424-014-1552-9>

- 548 Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M (2022) ColabFold:
549 making protein folding accessible to all. *Nat Methods* 19: 679-682.
550 <https://doi.org/10.1038/s41592-022-01488-1>
- 551 Mucha BE, Hennekam RCM, Sisodiya S, Campeau PM (1993) TBC1D24-Related Disorders. In:
552 Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds)
553 *GeneReviews*((R)), Seattle (WA)
- 554 Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. *Genome Res* 11: 863-
555 74. <https://doi.org/10.1101/gr.176601>
- 556 Niu M, McGrath M, Sammon D, Gardner S, Morgan RM, Di Maio A, Liu Y, Bubeck D,
557 Hohenester E (2023) Structure of the transmembrane protein 2 (TMEM2) ectodomain
558 and its apparent lack of hyaluronidase activity. *Wellcome Open Res* 8: 76.
559 <https://doi.org/10.12688/wellcomeopenres.18937.2>
- 560 Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, Shen J, Chapin A,
561 Boczek NJ, Schimmenti LA, Murry JB, Hasadsri L, Nara K, Kenna M, Booth KT, Azaiez
562 H, Griffith A, Avraham KB, Kremer H, Rehm HL, Amr SS, Abou Tayoun AN, ClinGen
563 Hearing Loss Clinical Domain Working G (2018) Expert specification of the ACMG/AMP
564 variant interpretation guidelines for genetic hearing loss. *Hum Mutat* 39: 1593-1613.
565 <https://doi.org/10.1002/humu.23630>
- 566 Perry J, Redfield S, Oza A, Rouse S, Stewart C, Khela H, Srinivasan T, Albano V, Shearer E,
567 Kenna M (2023) Exome Sequencing Expands the Genetic Diagnostic Spectrum for
568 Pediatric Hearing Loss. *Laryngoscope* 133: 2417-2424.
569 <https://doi.org/10.1002/lary.30507>
- 570 Petit C, Richardson GP (2009) Linking genes underlying deafness to hair-bundle development
571 and function. *Nat Neurosci* 12: 703-10. <https://doi.org/10.1038/nn.2330>
- 572 Rehman AU, Friedman TB, Griffith AJ (2017) Unresolved questions regarding human hereditary
573 deafness. *Oral Dis* 23: 551-558. <https://doi.org/10.1111/odi.12516>
- 574 Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M (2019) CADD: predicting the
575 deleteriousness of variants throughout the human genome. *Nucleic Acids Res* 47: D886-
576 D894. <https://doi.org/10.1093/nar/gky1016>
- 577 Rockowitz S, LeCompte N, Carmack M, Quitadamo A, Wang L, Park M, Knight D, Sexton E,
578 Smith L, Sheidley B, Field M, Holm IA, Brownstein CA, Agrawal PB, Kornetsky S, Poduri
579 A, Snapper SB, Beggs AH, Yu TW, Williams DA, Sliz P (2020) Children's rare disease
580 cohorts: an integrative research and clinical genomics initiative. *NPJ Genom Med* 5: 29.
581 <https://doi.org/10.1038/s41525-020-0137-0>
- 582 Rouse SL, Florentine MM, Taketa E, Chan DK (2022) Racial and ethnic disparities in genetic
583 testing for hearing loss: a systematic review and synthesis. *Hum Genet* 141: 485-494.
584 <https://doi.org/10.1007/s00439-021-02335-7>
- 585 Sato S, Miyazaki M, Fukuda S, Mizutani Y, Mizukami Y, Higashiyama S, Inoue S (2023) Human
586 TMEM2 is not a catalytic hyaluronidase, but a regulator of hyaluronan metabolism via
587 HYBID (KIAA1199/CEMIP) and HAS2 expression. *J Biol Chem* 299: 104826.
588 <https://doi.org/10.1016/j.jbc.2023.104826>
- 589 Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction
590 for the deep-sequencing age. *Nat Methods* 11: 361-2.
591 <https://doi.org/10.1038/nmeth.2890>
- 592 Shearer AE, Smith RJ (2015) Massively Parallel Sequencing for Genetic Diagnosis of Hearing
593 Loss: The New Standard of Care. *Otolaryngol Head Neck Surg* 153: 175-82.
594 <https://doi.org/10.1177/0194599815591156>
- 595 Shihab HA, Gough J, Mort M, Cooper DN, Day IN, Gaunt TR (2014) Ranking non-synonymous
596 single nucleotide polymorphisms based on disease concepts. *Hum Genomics* 8: 11.
597 <https://doi.org/10.1186/1479-7364-8-11>

- 598 Sloan-Heggen CM, Bierer AO, Shearer AE, Kolbe DL, Nishimura CJ, Frees KL, Ephraim SS,
599 Shibata SB, Booth KT, Campbell CA, Ranum PT, Weaver AE, Black-Ziegelbein EA,
600 Wang D, Azaiez H, Smith RJH (2016) Comprehensive genetic testing in the clinical
601 evaluation of 1119 patients with hearing loss. *Hum Genet* 135: 441-450.
602 <https://doi.org/10.1007/s00439-016-1648-8>
- 603 Smith RJ, Bale JF, Jr., White KR (2005) Sensorineural hearing loss in children. *Lancet* 365:
604 879-90. [https://doi.org/10.1016/S0140-6736\(05\)71047-3](https://doi.org/10.1016/S0140-6736(05)71047-3)
- 605 Vona B, Mazaheri N, Lin SJ, Dunbar LA, Maroofian R, Azaiez H, Booth KT, Vitry S, Rad A,
606 Ruschendorf F, Varshney P, Fowler B, Beetz C, Alagramam KN, Murphy D, Shariati G,
607 Sedaghat A, Houlden H, Petree C, VijayKumar S, Smith RJH, Haaf T, El-Amraoui A,
608 Bowl MR, Varshney GK, Galehdari H (2021) A biallelic variant in CLRN2 causes non-
609 syndromic hearing loss in humans. *Hum Genet* 140: 915-931.
610 <https://doi.org/10.1007/s00439-020-02254-z>
- 611 Wang L, Chen Q, Liu T, Bai T, Zhang M, Hu Y, Li J, Chang F (2023) Role and mechanism of
612 benzo[a]pyrene in the transformation of chronic obstructive pulmonary disease into lung
613 adenocarcinoma. *J Cancer Res Clin Oncol* 149: 4741-4760.
614 <https://doi.org/10.1007/s00432-022-04353-y>
- 615 Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C (2019) MetaDome:
616 Pathogenicity analysis of genetic variants through aggregation of homologous human
617 protein domains. *Hum Mutat* 40: 1030-1038. <https://doi.org/10.1002/humu.23798>
- 618 Wu X, Ivanchenko MV, Al Jandal H, Cicconet M, Indzhykulian AA, Corey DP (2019) PKHD1L1
619 is a coat protein of hair-cell stereocilia and is required for normal hearing. *Nat Commun*
620 10: 3801. <https://doi.org/10.1038/s41467-019-11712-w>
- 621 Yamamoto H, Tobisawa Y, Inubushi T, Irie F, Ohyama C, Yamaguchi Y (2017) A mammalian
622 homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after
623 cell-surface hyaluronidase. *J Biol Chem* 292: 7304-7313.
624 <https://doi.org/10.1074/jbc.M116.770149>
- 625 Yang Y, Pang Q, Hua M, Huangfu Z, Yan R, Liu W, Zhang W, Shi X, Xu Y, Shi J (2023)
626 Excavation of diagnostic biomarkers and construction of prognostic model for clear cell
627 renal cell carcinoma based on urine proteomics. *Front Oncol* 13: 1170567.
628 <https://doi.org/10.3389/fonc.2023.1170567>
- 629 Yoshida H, Nagaoka A, Kusaka-Kikushima A, Tobiishi M, Kawabata K, Sayo T, Sakai S,
630 Sugiyama Y, Enomoto H, Okada Y, Inoue S (2013) KIAA1199, a deafness gene of
631 unknown function, is a new hyaluronan binding protein involved in hyaluronan
632 depolymerization. *Proc Natl Acad Sci U S A* 110: 5612-7.
633 <https://doi.org/10.1073/pnas.1215432110>
- 634 Yu J, Wang G, Chen Z, Wan L, Zhou J, Cai J, Liu X, Wang Y (2023) Deficit of PKHD1L1 in the
635 dentate gyrus increases seizure susceptibility in mice. *Hum Mol Genet* 32: 506-519.
636 <https://doi.org/10.1093/hmg/ddac220>
- 637 Zheng C, Quan R, Xia EJ, Bhandari A, Zhang X (2019) Original tumour suppressor gene
638 polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell
639 progression. *Oncol Lett* 18: 3227-3235. <https://doi.org/10.3892/ol.2019.10632>

640

641

642

643 **Statements and Declarations**

644 **Acknowledgments**

645 We thank the families for their participation.

646 **Funding**

647 This work was supported by NIDCD K08 DC019716 to AES, the De Garay Family Fund to MAK
648 with support from the Boston Children's Rare Disease Cohort Initiative, and the German
649 Research Foundation (DFG) VO 2138/7-1 grant 469177153 to BV, and by NIH R01DC017166
650 (NIDCD) and R01DC020190 (NIDCD) to AAI. Funding for work in Pakistan was provided by the
651 University of the Punjab (SN).

652 **Author contributions**

653 SER and PD contributed equally as shared first authors and AAI, AES and BV contributed
654 equally as shared last authors. AES, PD, and AAI conceived the study. PD, TM, and AAI
655 designed methodology. PD and TM contributed software. MZ, PD, and AAI performed formal
656 analyses that were validated by MZ, MK, PD, TM, and AAI. MZ, HK, MK, SN, MAK, PD, TM,
657 AAI, and BV conducted the investigation process. HG, GS, MAK, AES, SER, and PD secured
658 patient and experimental resources. MZ, HG, GS, BV, SER, AES, PD, and AAI performed data
659 curation. BV, AES, PD, and AAI wrote the original draft. MZ, HK, MK, SN, HG, BV, SER, AES,
660 PD, and AAI contributed to reviewing and editing. BV, AES, SER, PD, and AAI prepared figures.
661 SN, AES, PD, and AAI provided supervision. BV, AES, and AAI oversaw project administration.
662 All authors reviewed and approved of the manuscript.

663 **Data Availability**

664 All data needed to evaluate the conclusions in the paper are present in the paper and/or the
665 Supplementary Materials. Additional data related to this paper may be requested from the
666 authors.

667 **Compliance with ethical standards**

668 **Conflict of interest**

669 Go Hun Seo is an employee of 3Billion, Inc. The other authors have no conflicts to declare.

670 **Ethics approval**

671 This study was approved by the institutional review boards of Boston Children’s Hospital (IRB P-
672 00031494), University Medical Center Göttingen (No. 3/2/16), and the School of Biological
673 Sciences, University of Punjab, Lahore, Pakistan (IRB No. 00005281).

674 **Consent to participate**

675 Written informed consent was obtained from all participants.

676 **Consent to publish**

677 Consent to publish was obtained from all participants.

678 Figure Legends

679 **Fig. 1. Pedigrees & Audiograms.** Pedigree and audiometric information for three families with
680 biallelic *PKHD1L1* variations. (a) Pedigrees for families 1-3. Each proband with SNHL is
681 indicated with shading and arrow. (b) Pure tone audiometry for probands 1-3; x represents
682 results for the left ear and o represents the right. Audiometric evaluation performed at 10-15-
683 years-old, for probands 1 and 3, and 6-10-years-old, for probands 2, respectively.

684
685
686 **Fig. 2. PKHD1L1 protein domain prediction and evolutionary analysis.** (a) Schematic of a
687 hair-cell stereocilia bundle under force stimulation highlighting the stereocilia surface coat. (b)
688 Protein domain composition prediction from SMART using the *Hs* PKHD1L1 protein sequence
689 as in NCBI accession code NP_803875.2, including the signal peptide (See Supplementary
690 Table S1). Positions of each variant reported in this study is presented with a green arrowhead.
691 The red star represents a newly predicted TMEM2-like domain. Black and purple arrow-headed
692 lines represent the sequence fragments used for AlphaFold2 modelling of IPT1-2, IPT5-6, and
693 TMEM2-like domain, respectively. (c) Topological description of *Hs* PKHD1L1 protein sequence
694 as a reference. (d-e) Multiple protein sequence alignments comparing IPT1 and IPT6 domains
695 from 10 different species, respectively (see Supplementary TableS1 for details about the
696 selected species and Supplementary Fig. S3 for full PKHD1L1 sequence alignment). IPT1 has a
697 sequence pairwise identity conservation of 82.3%, while IPT6 has a pairwise identity of 74.9%.
698 Missense variants are highlighted by green triangles. Blue circles represent cysteine residues
699 forming disulfide bonds showed in panels *f-i*. Each alignment was color-coded for sequence
700 similarity (35% threshold) using Jalview. White-colored residues show the lowest similarity and
701 dark blue report the highest (see Methods). Species were chosen based on sequence
702 availability and taxonomical diversity (Choudhary et al. 2020; De-la-Torre et al. 2018; Jaiganesh
703 et al. 2018). (f) Superposed AlphaFold2 models of both native *Hs* IPT1-2 (orange) and *Hs* IPT1-
704 2 p.(Gly120Ser) variant (mauve) are shown. (g) Higher magnification image of the mutated site.
705 S129 in lime and G129 in cyan. No apparent structural changes are predicted by AlphaFold2.
706 (h) Structural model of *Hs* IPT5-6 showing the native Gly1314 position. (i) Superposed *Hs* IPT5-
707 6 (orange) and *Hs* IPT5-6 p.(Gly1314Val) (mauve) structures showing a structural change
708 predicted by AlphaFold2 as a result of p.(Gly1314Val) substitution. β -strands and loops do not
709 overlap, with a dashed black arrow reporting the loop shift. (j) Higher magnification image of the
710 mutated site showing the conformation change of β -strands and loops. V1314 (lime) cause
711 steric hindrance in the area inducing an expanded conformation to the variant structure in
712 mauve. See dashed arrows.

713
714
715 **Fig. 3. PKHD1L1 structural modelling of the protein fragment containing the**
716 **p.(His2479Gln) variant.** Based on AlphaFold2 predictions, this fragment of PKHD1L1 shares a

717 common fold with the TMEM2 protein within the region carrying the p.(His2479Gln) variant. (a)
718 Protein sequence alignment of a protein segment of *Hs* TMEM2 against 10 different species of
719 PKHD1L1 proteins (See Supplementary Table S1 for details of the selected species,
720 Supplementary Fig. S4 for sequence alignment of this specific fragment, and Supplementary
721 Fig. S3 for full PKHD1L1 sequence alignment). Residue numbering for TMEM2 as in PDB: 8C6I
722 (Niu et al. 2023), while residue numbering for *Hs* PKHD1L1 as in NCBI accession code
723 NP_803875.2 with the signal peptide included (Supplementary Table S1, 26 residues are
724 suggested, see Methods). Green triangles point to the location of the human variant
725 p.(His2479Gln), orange circles (*left*) indicate 100% amino acid sequence identity for this
726 PKHD1L1 fragment between the *Hs*, *Pt*, and *Mm2* species (See supplementary Table S1 for
727 details about the selected species). Green circles represent depicted residues in panels *b-e*.
728 The alignment was color-coded for sequence similarity (35% threshold) using Jalview. White-
729 colored residues show the lowest similarity and dark blue report the highest (see Methods).
730 Species were chosen based on sequence availability and taxonomical diversity. (b) The
731 simulated protein structure covering the protein fragment highlighted by purple arrow-headed
732 line in Fig. 2b. Front view of the structure showing IPT14 linked to the PKHD1L1 TMEM2-like
733 domain. The red star points to the linker connection. Residues at the mutation site are depicted
734 as cyan sticks. (c) Side view from *panel a* showing a clear view of the stacked β -strand motifs.
735 (d) Superposed structural protein alignment between WT *Hs* PKHD1L1 TMEM2-like domain
736 model (orange) with the X-ray crystal structure of *Hs* TMEM2 protein (PDB: 8C6I, magenta).
737 Residues at the native TMEM2-histidine finger site are depicted as green sticks. (e) Higher
738 magnification image of the potential conserved histidine-finger site between PKHD1L1 (orange)
739 and TMEM2 (magenta) protein fragments and the Ni²⁺ ion shown as lime sphere. (f) Displayed
740 residues between both proteins surrounding the Ni²⁺-ion site highlighted in *panel a* in green
741 circles.

742
743

744 **Fig. 4. Thermodynamic and folding stability evaluation of two missense variants using**
745 **NanoDSF.** (a) NanoDSF melting temperatures for WT *Mm* IPT1-3 (orange) and *Mm* IPT1-3
746 p.(Gly129Ser) variant (pink). Measurements show at least three T_m peaks (orange dotted line)
747 for the WT IPT1-3, likely because the protein fragment includes multiple IPT domains that unfold
748 sequentially. Measured T_m values are shifted to the left (pink dotted line) showing a decrease of
749 the thermal folding stability. Temperatures are labeled for each T_m transition point. (b) Results
750 for WT *Mm* IPT5-6 and *Mm* IPT5-6 p.(Gly1314Val) showing a reduced thermal stability (2
751 replicates, see Methods section). Traces correspond to the normalized first derivate of the
752 fluorescence ratio showing the inflection point of the fluorescence ratio, which corresponds to
753 the melting temperature of the sample. T_{onset} values and protein purification experiments are
754 shown in Supplementary Fig. S5.

Table


Table 1. *PKHD1L1* variants identified.

Family	Chr8 location (g.)	Genomic (g.)	Coding DNA (c.)	Protein (p.)	Zyg	AF gnomAD (v.3.1.2)	MAF gnomAD (v3.1.2)	MAF Pop gnomAD (v3.1.2))	AF gnomAD (v.2.1.1)	MAF gnomAD (v.2.1.1)	MAF Pop gnomAD (v2.1.1)	SIFT	PP-2	FATHMM	MT	REVEL	CADD
1	109382539G>A	385G>A	385G>A	Gly129Ser	Het	0.000006576	0.00001471	European (non-Finnish)	-	-	-	0.165	0.995	-2.15	0.99	0.55	26.2
1	109439077G>T	3941G>T	3941G>T	Gly1314Val	Het	0.0003681	0.0007204	Ashkenazi Jewish	0.0002793	0.0005713	European (non-Finnish)	0.004	0.98	-2.56	1	0.86	26.6
2	109491899C>T	10141C>T	10141C>T	Arg3381Ter	Hom	0.00001979	0.0001936	East Asian	0.00004321	0.0002067	East Asian	-	-	-	1	-	39
3	109464269C>A	7437C>A	7437C>A	His2479Gln	Hom	0.00009864	0.003107	South Asian	0.0002259	0.001809	South Asian	0	0.88	-3.3	0.004	0.72	22.9


All variants are annotated according to NC_000008.11 (genomic) and NM_177531.6 (coding DNA). Residue position according to NP_803875.2 including the signal peptide (Supplementary Table S1). Abbreviations: AF, allele frequency; chr, chromosome; MAF, maximum allele frequency; MT, MutationTaster; Pop, population; PP2, PolyPhen-2; Zyg, zygosity

A Family 1


medRxiv preprint doi: <https://doi.org/10.1101/2023.10.08.23296081>; this version posted October 9, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/).




Family 2




Family 3




B Family 1








Family 2




Family 3





f Residue conservation

PKHD1L1	TMEM2
M2442	M521
H2444	M523
Y2474	Y547
H2477	H550
H2479	H552
L2480	L553
T2504	T583
H2506	H585
E2529	E608
D2530	D609

a**b**